ArticleNPJ breast cancer2025

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis.

Letizia Pontolillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.